NASDAQ:NEOS - Neos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.03 (-2.54%)
Get New Neos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEOS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Neos Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.15.

This chart shows the closing price for NEOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Neos Therapeutics. This rating has held steady since June 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/10/2020JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
8/12/2019BMO Capital MarketsLower Price TargetMarket Perform$4.00 ➝ $3.00Medium
6/12/2019Cantor FitzgeraldLower Price TargetOverweight$20.00 ➝ $10.00Medium
3/27/2019Cantor FitzgeraldReiterated RatingBuy$20.00Low
12/26/2018Cantor FitzgeraldSet Price TargetBuy$20.00Low
11/14/2018Wells Fargo & CompanyLower Price TargetOutperform$11.00 ➝ $6.00Medium
11/12/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Market Outperform$22.00 ➝ $10.00Medium
11/9/2018Cantor FitzgeraldReiterated RatingBuy$20.00Medium
8/9/2018Wells Fargo & CompanyLower Price TargetOutperform ➝ Buy$14.00 ➝ $11.00High
8/8/2018Cantor FitzgeraldReiterated RatingBuy$20.00Low
5/9/2018Cantor FitzgeraldReiterated RatingBuy$20.00Medium
3/23/2018Cantor FitzgeraldSet Price TargetBuy$20.00Low
3/17/2018Wells Fargo & CompanySet Price TargetBuy$14.00Low
3/15/2018Cantor FitzgeraldSet Price TargetBuy$20.00Low
1/31/2018BMO Capital MarketsDowngradeOutperform ➝ Market PerformHigh
1/8/2018Cantor FitzgeraldSet Price TargetBuy$20.00Medium
11/1/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/A
10/26/2017CowenReiterated RatingBuyN/A
10/26/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/A
10/18/2017Wells Fargo & CompanySet Price TargetBuy$14.00N/A
10/18/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$20.00Medium
8/9/2017Cantor FitzgeraldSet Price TargetBuy$20.00High
8/8/2017Royal Bank of CanadaSet Price TargetOutperform$12.00Medium
7/31/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$20.00High
6/20/2017BMO Capital MarketsReiterated RatingOutperform$15.00High
4/5/2017CowenInitiated CoverageOutperform$20.00High
3/20/2017UBS GroupReiterated RatingHoldN/A
3/17/2017UBS GroupDowngradeBuy ➝ Neutral$8.00N/A
3/11/2017BMO Capital MarketsReiterated RatingOutperform$15.00N/A
11/11/2016BMO Capital MarketsReiterated RatingBuyN/A
11/11/2016UBS GroupSet Price TargetBuy$12.00N/A
9/20/2016BMO Capital MarketsReiterated RatingBuy$15.00N/A
(Data available from 8/5/2016 forward)
Neos Therapeutics logo
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.
Read More

Today's Range

Now: $1.15
Low: $1.07
High: $1.23

50 Day Range

MA: $1.06
Low: $0.77
High: $1.18

52 Week Range

Now: $1.15
Low: $0.45
High: $1.68


429,971 shs

Average Volume

7,441,074 shs

Market Capitalization

$57.22 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Neos Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Neos Therapeutics in the last twelve months: JMP Securities, and Zacks Investment Research.
View the latest analyst ratings for NEOS.

What is the current price target for Neos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Neos Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Neos Therapeutics in the next year.
View the latest price targets for NEOS.

What is the current consensus analyst rating for Neos Therapeutics?

Neos Therapeutics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NEOS, but not buy more shares or sell existing shares.
View the latest ratings for NEOS.

What other companies compete with Neos Therapeutics?

How do I contact Neos Therapeutics' investor relations team?

Neos Therapeutics' physical mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company's listed phone number is 972-408-1300 and its investor relations email address is [email protected] The official website for Neos Therapeutics is